Ann Qin

602 total citations
23 papers, 267 citations indexed

About

Ann Qin is a scholar working on Oncology, Epidemiology and Hematology. According to data from OpenAlex, Ann Qin has authored 23 papers receiving a total of 267 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Epidemiology and 5 papers in Hematology. Recurrent topics in Ann Qin's work include Drug Transport and Resistance Mechanisms (8 papers), Liver Disease Diagnosis and Treatment (6 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Ann Qin is often cited by papers focused on Drug Transport and Resistance Mechanisms (8 papers), Liver Disease Diagnosis and Treatment (6 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Ann Qin collaborates with scholars based in United States, Czechia and France. Ann Qin's co-authors include Justin Q. Ly, Yuzhong Deng, Bianca M. Liederer, Xiaorong Liang, Ryan Takahashi, Edna F. Choo, Sheerin Shahidi-Latham, Lulu Yang, Peter S. Dragovich and Brian Dean and has published in prestigious journals such as Annals of the Rheumatic Diseases, Journal of Pharmaceutical Sciences and Clinical Pharmacology & Therapeutics.

In The Last Decade

Ann Qin

21 papers receiving 253 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ann Qin United States	11	81	79	48	41	33	23	267
Johannes J.M. Rood Netherlands	11	195 2.4×	108 1.4×	19 0.4×	15 0.4×	127 3.8×	16	360
Kevin Yang United States	14	229 2.8×	95 1.2×	9 0.2×	5 0.1×	21 0.6×	27	502
Dirk Bernicke Germany	8	229 2.8×	68 0.9×	81 1.7×	5 0.1×	16 0.5×	8	431
Emma S. Child United Kingdom	10	354 4.4×	235 3.0×	6 0.1×	7 0.2×	16 0.5×	16	560
Jorge Gomez‐Galeno United States	12	332 4.1×	39 0.5×	4 0.1×	26 0.6×	7 0.2×	17	626
Kunkun Han China	18	458 5.7×	205 2.6×	6 0.1×	21 0.5×	28 0.8×	24	630
Tianyu Wang China	14	193 2.4×	310 3.9×	17 0.4×	8 0.2×	7 0.2×	33	551
Álvaro Lorente‐Macías Spain	6	165 2.0×	60 0.8×	3 0.1×	10 0.2×	23 0.7×	15	345
Silpa Narayanan United States	10	304 3.8×	193 2.4×	4 0.1×	7 0.2×	17 0.5×	18	518
Upasana Ray United States	12	346 4.3×	124 1.6×	16 0.3×	6 0.1×	15 0.5×	19	530

Countries citing papers authored by Ann Qin

Since Specialization

Citations

This map shows the geographic impact of Ann Qin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann Qin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann Qin more than expected).

Fields of papers citing papers by Ann Qin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann Qin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann Qin. The network helps show where Ann Qin may publish in the future.

Co-authorship network of co-authors of Ann Qin

This figure shows the co-authorship network connecting the top 25 collaborators of Ann Qin. A scholar is included among the top collaborators of Ann Qin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann Qin. Ann Qin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Younis, Islam R., Elijah J. Weber, Cara R. Nelson, et al.. (2025). Pharmacokinetics and Safety of Fenofibrate in Participants with Mild Hepatic Impairment or with Advanced Fibrosis due to Metabolic‐Associated Fatty Liver Disease. The Journal of Clinical Pharmacology. 65(7). 850–859.

Dauki, Anees M., Nishanthan Rajakumaraswamy, Torsten Trowe, et al.. (2024). Pharmacokinetics, pharmacodynamics, and safety of GS‐3583, a FLT3 agonist Fc fusion protein, from single‐ascending‐dose phase I study in healthy participants. Clinical and Translational Science. 17(8). e70011–e70011. 1 indexed citations

Younis, Islam R., Cara Nelson, Elijah J. Weber, et al.. (2024). Pharmacokinetics and Safety of Firsocostat, an Acetyl‐Coenzyme A Carboxylase Inhibitor, in Participants with Mild, Moderate, and Severe Hepatic Impairment. The Journal of Clinical Pharmacology. 64(7). 878–886. 2 indexed citations

Weber, Elijah J., Islam R. Younis, Cara Nelson, et al.. (2024). Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug–Drug Interactions for Firsocostat, a Liver-Targeted Inhibitor of Acetyl-CoA Carboxylase. Clinical Pharmacokinetics. 63(10). 1423–1434. 3 indexed citations

Qin, Ann, Thomas Tarnowski, Kah Hiing John Ling, et al.. (2023). Plasma Protein Binding Determination for Unstable Ester Prodrugs: Remdesivir and Tenofovir Alafenamide. Journal of Pharmaceutical Sciences. 112(12). 3224–3232. 2 indexed citations

Younis, Islam R., Cara Nelson, Dora Ding, et al.. (2023). Effect of Renal Impairment on the Pharmacokinetics of Firsocostat, an Acetyl‐Coenzyme A Carboxylase Inhibitor, and Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist. The Journal of Clinical Pharmacology. 63(5). 560–568. 4 indexed citations

Hsueh, Chia‐Hsiang, et al.. (2021). Evaluation of the potential drug interactions mediated through P‐gp, OCT2, and MATE1/2K with filgotinib in healthy subjects. Clinical and Translational Science. 15(2). 361–370. 8 indexed citations

Begley, Rebecca, et al.. (2020). Lack of Drug‐Drug Interaction Between Filgotinib, a Selective JAK1 Inhibitor, and Oral Hormonal Contraceptives Levonorgestrel/Ethinyl Estradiol in Healthy Volunteers. Clinical Pharmacology in Drug Development. 10(4). 376–383. 11 indexed citations

Kirby, Brian J., Justin D. Lutz, Kimberly L. Garrison, et al.. (2020). Organic Anion Transporting Polypeptide Inhibition Dramatically Increases Plasma Exposure but not Pharmacodynamic Effect nor Inferred Hepatic Intracellular Exposure of Firsocostat. Clinical Pharmacology & Therapeutics. 109(5). 1334–1341. 10 indexed citations

10.

Zheng, Hao, et al.. (2019). The Relative Bioavailability and Effects of Food and Acid‐Reducing Agents on Filgotinib Tablets in Healthy Subjects. Clinical Pharmacology in Drug Development. 8(5). 585–594. 16 indexed citations

11.

Xin, Yan, Hao Zheng, Chohee Yun, et al.. (2019). Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects. Clinical Pharmacology in Drug Development. 9(1). 32–40. 7 indexed citations

12.

Ly, Justin Q., et al.. (2017). Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 Transgenic Mouse Models To Assess the Magnitude of CYP3A4 Mediated Drug–Drug Interactions. Molecular Pharmaceutics. 14(5). 1754–1759. 21 indexed citations

13.

Choo, Edna F., Sarah Woolsey, Kevin DeMent, et al.. (2015). Use of Transgenic Mouse Models to Understand the Oral Disposition and Drug-Drug Interaction Potential of Cobimetinib, a MEK Inhibitor. Drug Metabolism and Disposition. 43(6). 864–869. 15 indexed citations

14.

Qin, Ann, Xiaorong Liang, Yuzhong Deng, Brian Dean, & Sheerin Shahidi-Latham. (2015). Collagenase as an Effective Tool for Drug Quantitation in Tissues. Bioanalysis. 7(9). 1069–1079. 2 indexed citations

15.

Chiang, Po‐Chang, Stephen E. Gould, Michelle Nannini, et al.. (2014). Nanosuspension delivery of paclitaxel to xenograft mice can alter drug disposition and anti-tumor activity. Nanoscale Research Letters. 9(1). 156–156. 12 indexed citations

16.

Liang, Xiaorong, Lulu Yang, Ann Qin, et al.. (2014). Measuring Nad ⁺ Levels in Mouse Blood and Tissue Samples Via A Surrogate Matrix Approach Using LC–MS/MS. Bioanalysis. 6(11). 1445–1457. 25 indexed citations

17.

Chiang, Po‐Chang, Yong Cui, Yingqing Ran, et al.. (2013). In Vitro and In Vivo Evaluation of Amorphous Solid Dispersions Generated by Different Bench-Scale Processes, Using Griseofulvin as a Model Compound. The AAPS Journal. 15(2). 608–617. 28 indexed citations

18.

O’Brien, Thomas, Jason Oeh, Yang Xiao, et al.. (2013). Supplementation of Nicotinic Acid with NAMPT Inhibitors Results in Loss of In Vivo Efficacy in NAPRT1-Deficient Tumor Models. Neoplasia. 15(12). 1314–IN3. 47 indexed citations

19.

Sampath, Deepak, Jason Oeh, Yang Xiao, et al.. (2013). Abstract B154: Co-administration of nicotinic acid with NAMPT small molecule inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.. Molecular Cancer Therapeutics. 12(11_Supplement). B154–B154. 1 indexed citations

20.

Neitz, R. Jeffrey, Andrei W. Konradi, Hing L. Sham, et al.. (2011). Highly selective c-Jun N-terminal kinase (JNK) 3 inhibitors with in vitro CNS-like pharmacokinetic properties II. Central core replacement. Bioorganic & Medicinal Chemistry Letters. 21(12). 3726–3729. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact